YXYanyong Xu

Yanyong Xu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yanyong Xu has a total of 113 co-authors. Here are the top co-authors by number of shared publications:

  • Chencheng Hu

    Department of Pathology, School of Basic Medical Sciences, Fudan University, Shanghai, 200032, China

    6 shared publications
  • Shuwei Hu

    Key Laboratory of Metabolism and Molecular Medicine of the Ministry of Education, Department of Pathology of School of Basic Medical Sciences, Frontier Innovation Center, Fudan University Shanghai, Shanghai, 200032, China

    6 shared publications
  • Yanqiao Zhang

    Department of Internal Medicine and the Translational Cardiovascular Research Center, University of Arizona College of Medicine - Phoenix, Phoenix, USA

    5 shared publications
  • Zhonghua Zhao

    Department of Pathology, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China

    5 shared publications
  • Huijuan Wu

    Department of Pathology, School of Basic Medical Sciences, Fudan University, Shanghai, China

    4 shared publications
  • Jiaoyu Shi

    Department of Pathology, School of Basic Medical Sciences, Fudan University, Shanghai, People’s Republic of China

    3 shared publications

Latest Publications

  • HSF1-UCHL1 transcriptional axis protects against MASLD via regulation of PPARα protein stability

    by Yuxiang Cao, Xiangcheng Fan, Meiyao Meng, Yingwen Wang, Shuang Liu, Lijun Zhu, Guangyu Shan, Yinzhao Zhong, Yingying Guo, Wenhao Zhou, et al.


  • Open Access

    Exogenous creatine supplementation promotes tumor metastasis via megakaryocyte creatine kinase B-STAT5B signaling

    by Sisi Xie, Ruibo Chen, Xiaoting Sun, Xiaolei Ni, Yuting Wu, Linli Cai, Yangyi Chen, Shuangming Lin, Mei Rao, Liling Chen, et al.

    Creatine supplementation is widely used in sports and increasingly popular among exercising individuals. Although the physiological role of creatine has been extensively studied, the creatine biology in pathological conditions remains poorly understood. Here we report that exogenous creatine supplementation promotes tumor metastasis via platelet activation mechanism in various mouse models and humans. Mechanistically, creatine supplementation increases megakaryocyte creatine levels and upregulates creatine kinase B (CKB). Unbiased phosphoproteomics reveals that a CKB-downstream, non-canonical STAT5B phosphorylation instigates various platelet functional genes, leading to hyperactive, metastasis-promoting platelets. Megakaryocyte-specific knockout of the creatine transporter Slc6a8 or Stat5b , as well as pharmacological inhibition of STAT5, ablates the creatine-augmented platelet hyperactivity and prevents consequent metastasis in mice. Importantly, creatine supplementation in healthy volunteers results in hyperactive peripheral platelets that increase metastasis risks. Together, our study sheds mechanistic insights into the creatine-induced metastasis and provides an anti-metastatic therapeutic paradigm by targeting megakaryocyte creatine metabolism.

  • Open Access

    Hepatic activating transcription factor 3 protects against systemic inflammation by attenuating lipotoxicity

    by Chencheng Hu, Qian Yang, Runzhi Yu, Shuwei Hu, Bing Meng, Yanyong Xu

  • Open Access

    Transcription factors, metabolic dysfunction-associated fatty liver disease, and therapeutic implications

    by Shuwei Hu, Yingjie Ai, Chencheng Hu, Fathima N. Cassim Bawa, Yanyong Xu

    Metabolic dysfunction-associated fatty liver disease (MAFLD) encompasses a spectrum of liver diseases ranging from metabolic dysfunction-associated fatty liver to metabolic dysfunction-associated steatohepatitis, which may progress to liver cirrhosis and hepatocellular carcinoma. Several mechanisms, including obesity, insulin resistance, dyslipidemia, inflammation, apoptosis, mitochondrial dysfunction, and reactive oxygen species, have been proposed to underlie the progression of MAFLD. Transcription factors are proteins that specifically bind to DNA sequences to regulate the transcription of target genes. Numerous transcription factors regulate MAFLD by modulating the transcription of genes involved in steatosis, inflammation, apoptosis, and fibrosis. Here, we review the pathological factors associated with MAFLD, with a particular emphasis on the transcription factors that contribute to the progression of MAFLD and their therapeutic implications.


  • Top Cited Papers

    FABP5+ lipid-loaded macrophages process tumour-derived unsaturated fatty acid signal to suppress T-cell antitumour immunity

    by Xuguang Yang, Bo Deng, Weiwei Zhao, Yangyang Guo, Yaqi Wan, Zhihao Wu, Sheng Su, Jingyan Gu, Xiaoqian Hu, Wenxue Feng, et al.


  • Open Access

    Editorial: Antioxidants and inflammatory immune-related diseases

    by Pengfei Xu, Zunnan Huang, Yanyong Xu, Huanxiang Liu, Yuyu Liu, Ling Wang

    Antioxidants and inflammatory immune-related diseases The interplay between antioxidants and inflammatory immune-related diseases has gained significant attention in recent years. Antioxidants, known for combating oxidative stress, have emerged as potential modulators of inflammation, a process intricately linked to various immune-related conditions (1). Understanding the role of antioxidants in managing these diseases holds the promise for advancing preventive and therapeutic strategies. This editorial explores the multifaceted connection between antioxidants and inflammation, highlighting their potential health implications. Inflammation, the body's natural response to injury or infection, is crucial for maintaining homeostasis (2). However, chronic inflammation can lead to the development and progression of numerous immune-related diseases, such as rheumatoid arthritis, inflammatory bowel disease (IBD), and certain cancers (3). The complex cellular and molecular mechanisms of chronic inflammation highlight its significant impact on overall health. The relationship between antioxidants and inflammatory immune-related diseases centers on oxidative stress. Free radicals, byproducts of normal cellular processes, can cause oxidative damage, triggering and sustaining inflammation (4). Antioxidants neutralize free radicals, thereby counteracting oxidative stress and potentially modulating the inflammatory response. This modulation may alleviate symptoms and slow the progression of inflammatory diseases, presenting a compelling area for exploration. Integrating antioxidant-rich foods into one's daily diet holds significant practical value for holistic health (5). A balanced and diverse diet, rich in antioxidants like vitamin C, vitamin E, Frontiers in Immunology frontiersin.org 01


  • Open Access

    Atf3-mediated metabolic reprogramming in hepatic macrophage orchestrates metabolic dysfunction–associated steatohepatitis

    by Shuwei Hu, Rui Li, Dongxu Gong, Pei Hu, Jitu Xu, Yingjie Ai, Xiaojie Zhao, Chencheng Hu, Minghuan Xu, Chenxi Liu, et al.

    Metabolic dysfunction–associated steatohepatitis (MASH) is regulated by complex interplay between the macrophages and surrounding cells in the liver. Here, we show that Atf3 regulates glucose-fatty acid cycle in macrophages attenuates hepatocyte steatosis, and fibrogenesis in hepatic stellate cells (HSCs). Overexpression of Atf3 in macrophages protects against the development of MASH in Western diet–fed mice, whereas Atf3 ablation has the opposite effect. Mechanistically, Atf3 improves the reduction of fatty acid oxidation induced by glucose via forkhead box O1 (FoxO1) and Cd36. Atf3 inhibits FoxO1 activity via blocking Hdac1-mediated FoxO1 deacetylation at K242, K245, and K262 and increases Zdhhc4/5-mediated CD36 palmitoylation at C3, C7, C464, and C466; furthermore, macrophage Atf3 decreases hepatocytes lipogenesis and HSCs activation via retinol binding protein 4 (Rbp4). Anti-Rbp4 can prevent MASH progression that is induced by Atf3 deficiency in macrophages. This study identifies Atf3 as a regulator of glucose-fatty acid cycle. Targeting macrophage Atf3 or Rbp4 may be a plausible therapeutic strategy for MASH.


  • Open Access

    Hepatic FOXA3 overexpression prevents Western diet–induced obesity and MASH through TGR5

    by Raja Gopoju, Jiayou Wang, Xiaoli Pan, Shuwei Hu, Li Lin, Alyssa Clark, Yanyong Xu, Liya Yin, Xinwen Wang, Yanqiao Zhang


  • Hepatocytic lipocalin-2 controls HDL metabolism and atherosclerosis via Nedd4-1-SR-BI axis in mice

    by Shuwei Hu, Yingdong Zhu, Xiaojie Zhao, Rui Li, Guangze Shao, Dongxu Gong, Chencheng Hu, Hongjun Liu, Kexin Xu, Chenxi Liu, et al.


  • Open Access

    Hepatocyte Sirtuin 6 Protects against Atherosclerosis and Steatohepatitis by Regulating Lipid Homeostasis

    by Yingdong Zhu, Shuwei Hu, Xiaoli Pan, Raja Gopoju, Fathima N. Cassim Bawa, Liya Yin, Yanyong Xu, Yanqiao Zhang

    Histone deacetylase Sirtuin 6 (SIRT6) regulates many biological processes. SIRT6 is known to regulate hepatic lipid metabolism and inhibit the development of nonalcoholic fatty liver disease (NAFLD). We aimed to investigate the role of hepatocyte SIRT6 in the development of atherosclerosis and further characterize the mechanism underlying SIRT6’s effect on NAFLD. Ldlr−/− mice overexpressing or lacking hepatocyte SIRT6 were fed a Western diet for 16 weeks. The role of hepatic SIRT6 in the development of nonalcoholic steatohepatitis (NASH), atherosclerosis, and obesity was investigated. We also investigated whether p53 participates in the pathogenesis of NAFLD in mice overexpressing hepatic SIRT6. Our data show that loss of hepatocyte SIRT6 aggravated the development of NAFLD, atherosclerosis, and obesity in Ldlr−/− mice, whereas adeno-associated virus (AAV)-mediated overexpression of human SIRT6 in the liver had opposite effects. Mechanistically, hepatocyte SIRT6 likely inhibited the development of NAFLD by inhibiting lipogenesis, lipid droplet formation, and p53 signaling. Hepatocyte SIRT6 also likely inhibited the development of atherosclerosis by inhibiting intestinal lipid absorption and hepatic VLDL secretion. Hepatic SIRT6 also increased energy expenditure. In conclusion, our data indicate that hepatocyte SIRT6 protects against atherosclerosis, NAFLD, and obesity by regulating lipid metabolism in the liver and intestine.